Fig. 1From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC studyPatient disposition. AEs adverse events, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, mITT modified intention-to-treat, TCZ-SC tocilizumab by subcutaneous injectionBack to article page